Back to top

Grifols doses first patients in two Gamunex-C trials

Grifols (GRFS) announced that the first patients have been dosed in two separate Phase 3 trials aiming to expand the U.S. labels for its signature ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Grifols, S.A. (GRFS)